
Novel Strategies for MM Management and Decision Support Tool
Chapter 2 of a 2-Part CE Podcast This activity is certified for CME/CNE/CPE credit. To participate and earn credit, visit us at https://www.impactedu.net/multiple-myeloma-decision-tool/. As MM progresses to relapsed/refractory MM (RRMM), the selection of an appropriate treatment regimen becomes more complex, requiring an assessment of severity, risk, and prior lines of therapy. Newer agents such as chimeric antigen receptor (CAR) T-cell therapies or bispecific antibody therapies may be indicated. Current treatment guidelines reflect these considerations. However, incorporating appropriate…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.